

Gayatri Amirthalingam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8175878/publications.pdf>

Version: 2024-02-01

46
papers

7,643
citations

257450
24
h-index

214800
47
g-index

62
all docs

62
docs citations

62
times ranked

10749
citing authors

#	ARTICLE	IF	CITATIONS
1	Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study. JMIR Public Health and Surveillance, 2022, 8, e25803.	2.6	1
2	Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. Journal of Infection, 2022, 84, 675-683.	3.3	87
3	Extended interval BNT162b2 vaccination enhances peak antibody generation. Npj Vaccines, 2022, 7, 14.	6.0	101
4	Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. New England Journal of Medicine, 2022, 386, 340-350.	27.0	501
5	Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. New England Journal of Medicine, 2022, 386, 1532-1546.	27.0	1,709
6	Long-Term Health-Related Quality of Life in Non-Hospitalized Coronavirus Disease 2019 (COVID-19) Cases With Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in England: Longitudinal Analysis and Cross-Sectional Comparison With Controls. Clinical Infectious Diseases, 2022, 75, e962-e973.	5.8	32
7	Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network. Journal of Infection, 2022, 84, 814-824.	3.3	8
8	Influenza and Respiratory Virus Surveillance, Vaccine Uptake, and Effectiveness at a Time of Cocirculating COVID-19: Protocol for the English Primary Care Sentinel System for 2020-2021. JMIR Public Health and Surveillance, 2021, 7, e24341.	2.6	22
9	Rapid community point-of-care testing for COVID-19 (RAPTOR-C19): protocol for a platform diagnostic study. Diagnostic and Prognostic Research, 2021, 5, 4.	1.8	7
10	Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021. Eurosurveillance, 2021, 26, .	7.0	34
11	Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nature Immunology, 2021, 22, 620-626.	14.5	320
12	The impact of social and physical distancing measures on COVID-19 activity in England: findings from a multi-tiered surveillance system. Eurosurveillance, 2021, 26, .	7.0	10
13	Adverse events of interest following influenza vaccination, a comparison of cell culture-based with egg-based alternatives: English sentinel network annual report paper 2019/20. Lancet Regional Health - Europe, The, 2021, 2, 100029.	5.6	7
14	Obstetric and perinatal health outcomes after pertussis vaccination during pregnancy in Ontario, Canada: a retrospective cohort study. CMAJ Open, 2021, 9, E349-E349.	2.4	9
15	Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. Journal of Infection, 2021, 82, 162-169.	3.3	61
16	Social determinants of pertussis and influenza vaccine uptake in pregnancy: a national cohort study in England using electronic health records. BMJ Open, 2021, 11, e046545.	1.9	11
17	Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK. Emerging Infectious Diseases, 2021, 27, 1795-1801.	4.3	18
18	Retrospective cohort study investigating extent of pertussis transmission during a boarding school outbreak, England, December 2017 to June 2018. Eurosurveillance, 2021, 26, .	7.0	4

#	ARTICLE	IF	CITATIONS
19	Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of Medicine, 2021, 385, 585-594.	27.0	2,411
20	mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant. ELife, 2021, 10, .	6.0	28
21	Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5â€“6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis. The Lancet Healthy Longevity, 2021, 2, e554-e560.	4.6	34
22	JMM Profile: Bordetella pertussis and whooping cough (pertussis): still a significant cause of infant morbidity and mortality, but vaccine-preventable. Journal of Medical Microbiology, 2021, 70, .	1.8	4
23	Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. Nature Communications, 2021, 12, 7217.	12.8	80
24	Delivering prenatal pertussis vaccine through maternity services in England: What is the impact on vaccine coverage?. Vaccine, 2020, 38, 5332-5336.	3.8	7
25	Impact of the herpes zoster vaccination programme on hospitalised and general practice consulted herpes zoster in the 5 years after its introduction in England: a population-based study. BMJ Open, 2020, 10, e037458.	1.9	8
26	Excess mortality in the first COVID pandemic peak: cross-sectional analyses of the impact of age, sex, ethnicity, household size, and long-term conditions in people of known SARS-CoV-2 status in England. British Journal of General Practice, 2020, 70, e890-e898.	1.4	51
27	Disparities in the excess risk of mortality in the first wave of COVID-19: Cross sectional study of the English sentinel network. Journal of Infection, 2020, 81, 785-792.	3.3	36
28	Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis. BMJ Open, 2020, 10, e034886.	1.9	14
29	Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infectious Diseases, The, 2020, 20, 1034-1042.	9.1	493
30	Emergence of a Novel Coronavirus (COVID-19): Protocol for Extending Surveillance Used by the Royal College of General Practitioners Research and Surveillance Centre and Public Health England. JMIR Public Health and Surveillance, 2020, 6, e18606.	2.6	66
31	The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: Protocol to Develop Extended COVID-19 Surveillance and Trial Platforms. JMIR Public Health and Surveillance, 2020, 6, e19773.	2.6	44
32	The Use of Quasi-experimental Designs for Vaccine Evaluation. Clinical Infectious Diseases, 2019, 68, 1769-1776.	5.8	20
33	Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study. Lancet Public Health, The, 2018, 3, e82-e90.	10.0	57
34	Effectiveness of herpes zoster vaccination in an older United Kingdom population. Vaccine, 2018, 36, 2371-2377.	3.8	39
35	Vaccination in pregnancy: Attitudes of nurses, midwives and health visitors in England. Human Vaccines and Immunotherapeutics, 2018, 14, 179-188.	3.3	50
36	Hospitalisation of preterm infants with pertussis in the context of a maternal vaccination programme in England. Archives of Disease in Childhood, 2018, 103, 224-229.	1.9	22

#	ARTICLE	IF	CITATIONS
37	Review of vaccination in pregnancy to prevent pertussis in early infancy. Journal of Medical Microbiology, 2018, 67, 1426-1456.	1.8	80
38	RCGP Research and Surveillance Centre Annual Report 2014â€“2015: disparities in presentations to primary care. British Journal of General Practice, 2017, 67, e29-e40.	1.4	33
39	Sociodemographic predictors of variation in coverage of the national shingles vaccination programme in England, 2014/15. Vaccine, 2017, 35, 2372-2378.	3.8	21
40	Survey of Household Contacts of Infants With Laboratory-confirmed Pertussis Infection During a National Pertussis Outbreak in England and Wales. Pediatric Infectious Disease Journal, 2017, 36, 140-145.	2.0	21
41	Sustained Effectiveness of the Maternal Pertussis Immunization Program in England 3 Years Following Introduction. Clinical Infectious Diseases, 2016, 63, S236-S243.	5.8	223
42	Should the UK introduce a universal childhood varicella vaccination programme?. Archives of Disease in Childhood, 2016, 101, 2-3.	1.9	8
43	Oral Fluid Testing for Pertussis, England and Wales, June 2007â€“August 2009. Emerging Infectious Diseases, 2014, 20, 968-975.	4.3	22
44	Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet, The, 2014, 384, 1521-1528.	13.7	593
45	Strategies to control pertussis in infants. Archives of Disease in Childhood, 2013, 98, 552-555.	1.9	71
46	Accelerating Control of Pertussis in England and Wales. Emerging Infectious Diseases, 2012, 18, 38-47.	4.3	74